Pyridine coupled pyrazole analogues as lethal weapon against MRSA: An in-vitro and in-silico approach

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Antimicrobial Research

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat due to increasing multidrug resistance.
• Existing treatment options for MRSA infections are becoming less effective, necessitating the development of novel antimicrobial agents.

Purpose of the Study:

• To synthesize and evaluate pyridine-coupled pyrazoles as potential antimicrobial agents against MRSA.
• To identify potent compounds with significant antibacterial activity and investigate their mechanism of action.

Main Methods:

• Synthesis of a series of pyridine-coupled pyrazoles.
• Characterization using FT-IR, 1H NMR, and Mass spectroscopy.
• Screening for minimum inhibitory concentrations (MIC) against MRSA.
• Assessing bacterial cell membrane damage via potassium efflux and cellular content leakage.
• Anticoagulant activity assessment, molecular docking, and molecular dynamics simulations.

Main Results:

• Fourteen active pyridine-coupled pyrazole compounds were synthesized and characterized.
• Compound 6d demonstrated potent antibacterial activity against MRSA with an MIC of 21 μg/mL.
• Studies indicated that compound 6d causes bacterial cell membrane damage.
• Molecular docking revealed that the pyridine ring of the analogues interacts with key MRSA proteins (Staphylocoagulase and PBP2a).

Conclusions:

• Pyridine-coupled pyrazoles represent a promising class of compounds for developing new anti-MRSA therapies.
• Compound 6d is a lead candidate for further investigation due to its potent activity and favorable interaction with MRSA targets.
• The findings provide a foundation for designing more effective antimicrobial agents against resistant bacterial strains.